TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06113016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive handout on physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive handout on physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive individually tailored exercise intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Receive individually tailored exercise intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fisetin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT05006833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Provider Training - Bundled Approach
Description: At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Provider Training - Bundled Approach
Description: At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Provider Training - Bundled Approach
Description: At each clinic randomized to bundled training, providers will be invited to participate in one, in-clinic, group-based training. Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on introducing the HPV vaccine in a bundle of the other two adolescent vaccines (Tdap and MenACWY).
Study: NCT06113016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05006833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Provider Training - Benefits Approach
Description: At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
Study: NCT06113016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06113016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05777863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Description: A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
Study: NCT05006833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Provider Training - Benefits Approach
Description: At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Bundled Approach
Description: Text messages sent to parents will focus on receiving all three adolescent vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Bundled Approach
Description: Text messages sent to parents will focus on receiving all three adolescent vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Bundled Approach
Description: Text messages sent to parents will focus on receiving all three adolescent vaccines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Benefits Approach
Description: Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Benefits Approach
Description: Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
Study: NCT05052892

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: All patients underwent measurement of HVPG under local anesthesia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: All patients underwent measurement of HVPG under local anesthesia.
Study: NCT05213221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg, subcutaneous injection, q3w

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first TACE will be started on d1, and the subsequent TACE will be performed on demand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
Study: NCT05540184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg
Description: Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg
Description: Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 MG
Description: allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
Study: NCT05006833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Benefits Approach
Description: Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
Study: NCT05277935

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of the WeCancer app combined with the smartwatch.
Description: To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
Study: NCT06511648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib monotherapy
Description: Patients will receive treatment with erdafitinib alone (cohort 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab and Erdafitinib combination
Description: Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
Study: NCT05126953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: samfilcon A Lenses with EPG01 Packaging Solution
Description: samfilcon A Lenses with EPG01 Packaging Solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B+L Ultra Lenses
Description: Commercially available Biotrue ONEday lenses
Study: NCT05895071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5%potassium hydroxide
Description: . In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen
Description: in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
Study: NCT04538573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Patients in this group will be offered to use Oculus Rift goggles while undergoing the burn treatments, dressing changes and hydrotherapy to reduce pain and anxiety during treatment. The goggles will display Dreamland, a virtual reality videogame created by our team to maximize fun, diminish difficulty, and motion sickness. The system will be available 5 minutes before treatment to the patient in order to ease acclimatation to the goggles until the end of the treatment session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard pharmacological care as per the unit's protocol will serve as the control for half of the duration of every treatment session. It consists of different analgesic and sedative medication used in combination in order to help patients go through the procedure. The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.~Use of any co-interventions for pain or anxiety management (music, comforting, child life specialist or other) during this sequence will be documented.
Study: NCT04697316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
Study: NCT06176560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Oral Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Oral Formulation
Study: NCT05546918

Intervention type: OTHER
Intervention: survey, interviews and focus groups
Description: The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups

Intervention type: OTHER
Intervention: survey, interviews and focus groups
Description: The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups
Study: NCT04953299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Imagery training
Description: Behavioural intervention focused upon motivation and reaching achievable goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS 12 week weight loss programme
Description: The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
Study: NCT05142657

Intervention type: OTHER
Intervention: diet survey
Description: Dietary survey applied to all participants

Intervention type: OTHER
Intervention: diet survey
Description: Dietary survey applied to all participants
Study: NCT05157672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon (2 g)
Description: oral capsules, 2 g
Study: NCT05828134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein-enriched soup
Description: The participants in experimental group have a protein-enriched soup a day and do exercise a week
Study: NCT05795296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: 5mg po, d1-d14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200mg ivgtt, d1, q3w
Study: NCT06161701

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06120660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy
Study: NCT05960422

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal Sciatic Nerve Block
Description: Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
Study: NCT04846439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T infusion
Description: Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
Study: NCT04740346

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography, Chest X-ray, and blood test
Description: CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
Study: NCT05179850

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic Algorithm
Description: Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic Algorithm
Description: Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
Study: NCT04740346

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography, Chest X-ray, and blood test
Description: CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
Study: NCT05958732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somato-sensorial exercises therapy
Description: It includes exercises, which is already mentioned in the arm description.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Therapy
Description: It Includes routine exercises for the stroke patient the detail is already given in the arm description.
Study: NCT05846919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: face-mask preoxygenation
Description: face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.
Study: NCT05958732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: It Includes routine exercises for the stroke patient the detail is already given in the arm description.
Study: NCT05846919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HFNOC preoxygenation
Description: HFNOC preoxygenation (flow 2 L/kg/minute, max 6 L/minute) with 100 % oxygen for three minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNOC + face-mask preoxygenation
Description: HFNOC (flow 2 L/kg/minute) + face-mask preoxygenation (flow 2 L/kg/minute, max 6 L/minute) - with 100 % oxygen for three minutes.
Study: NCT04458168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Purposeful app
Description: Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Purposeful app
Description: Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Purposeful app
Description: Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment.
Study: NCT05795439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet
Description: The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.